Show simple item record

Phase III evaluation of once-daily, oral therapy with ICL670 (Exjade (R)) versus deferoxamine in patients with beta-thalassemia and transfusional hemosiderosis

dc.contributor.authorJanka-Schaub, G
dc.contributor.authorAlberti, D
dc.contributor.authorGiardina, P
dc.contributor.authorOpitz, H
dc.contributor.authorRessayre-Djaffer, C
dc.contributor.authorCappellini, M
dc.contributor.authorBejaoui, M
dc.contributor.authorPerrotta, S
dc.contributor.authorAgaoglu, L
dc.contributor.authorKattamis, A
dc.date.accessioned2021-03-03T15:00:07Z
dc.date.available2021-03-03T15:00:07Z
dc.identifier.citationCappellini M., Bejaoui M., Perrotta S., Agaoglu L., Kattamis A., Giardina P., Janka-Schaub G., Opitz H., Ressayre-Djaffer C., Alberti D., "Phase III evaluation of once-daily, oral therapy with ICL670 (Exjade (R)) versus deferoxamine in patients with beta-thalassemia and transfusional hemosiderosis", 46th Annual Meeting of the American-Society-of-Hematology, California, Amerika Birleşik Devletleri, 4 - 07 Aralık 2004, cilt.104
dc.identifier.othervv_1032021
dc.identifier.otherav_3c9df24f-6a3d-4677-baa0-bd856249404b
dc.identifier.urihttp://hdl.handle.net/20.500.12627/44668
dc.identifier.urihttps://doi.org/10.1182/blood.v104.11.3619.3619
dc.language.isoeng
dc.subjectDahili Tıp Bilimleri
dc.subjectİç Hastalıkları
dc.subjectHematoloji
dc.subjectTıp
dc.subjectSağlık Bilimleri
dc.subjectKlinik Tıp (MED)
dc.subjectKlinik Tıp
dc.subjectHEMATOLOJİ
dc.titlePhase III evaluation of once-daily, oral therapy with ICL670 (Exjade (R)) versus deferoxamine in patients with beta-thalassemia and transfusional hemosiderosis
dc.typeBildiri
dc.contributor.department, ,
dc.identifier.volume104
dc.contributor.firstauthorID130353


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record